At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer's disease, ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.